Change over period: —
NSE · SUVEN
SUVEN LIFE S
-32.2% from the 52-week high · +109.8% above the low
Suven Life Sciences Ltd. engages on discovering, developing, and commercializing novel pharmaceutical products which are used in classic therapies. The company is headquartered in Hyderabad, Telangana and currently employs 117 full-time employees. The firm is focused on discovering and developing new chemical entities (NCEs), which are central nervous system therapies for the treatment of cognitive disorders, depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastrointestinal motility disorders. Its research targets include serotonin 6 receptor, serotonin 4 receptor, histamine 3 receptor, Nicotinic acetylcholine (Alpha4beta2) receptor, muscarinic M1 receptor, muscarinic M4 receptor, multimodal and P2X purinoceptor 7 receptor. The company provides a range of Drug Discovery and Development Support Services (DDDSS). The firm offers research services specializing in synthetic, medicinal and analytical chemistry, in-vitro assay development and screening, drug metabolism and pharmacokinetics, toxicology and safety pharmacology, bioanalysis, and NCE formulations.
The short version. SUVEN LIFE S reported revenue of ₹1 crore for Sep 2026, up 0.0% from a year earlier. Net profit was ₹-107 crore. Return on equity was -46.7% in Mar 2026. Promoter holding was 65.47% in Sep 2026, down 4.80 points over 8 quarters.
1 · The price
How has the stock traded?
SUVEN LIFE S trades 32.2% below its 52-week high and 109.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹1 cr.
511.7 pts lower than a year earlier.
Revenue compounded at -1.5% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 4 | 2 | 3 | 1 | 2 | 1 | 2 |
| Net profit | -107 | -128 | -46 | -102 | -77 | -52 | -44 | -39 |
| Net margin % | -8922.3 | -3578.7 | -2999.5 | -3628.8 | -8410.6 | -2759.8 | -2995.6 | -2429.8 |
| EPS (₹) | -3.78 | -4.83 | -1.73 | -4.48 | -3.4 | -2.36 | -2.02 | -1.79 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7 | 7 | 12 | 14 | 12 | 13 | 14 | 664 |
| Net profit | -276 | -161 | -105 | -118 | -122 | -72 | -94 | 87 |
| Net margin % | -3884.1 | -2415.1 | -898.6 | -873.5 | -1030.0 | -535.3 | -653.6 | 13.1 |
| EPS (₹) | -10.48 | -7.37 | -4.82 | -5.42 | -5.59 | -3.78 | -4.93 | 4.55 |
3 · The quality
How well does it turn capital into profit?
Return on equity was -46.7% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | -46.7 | -146.2 | -38.9 | -31.5 |
| Return on capital % | -46.6 | -143.9 | -39.0 | -31.2 |
| EBITDA margin % | -1285.7 | -882.3 | -302.9 | -506.8 |
| Net margin % | -1313.1 | -915.8 | -320.1 | -537.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -1.5% | -0.2% |
| Profit CAGR | 32.7% | 30.8% |
4 · The owners
Who holds it, and are they adding?
Down 4.8 pts over 8 quarters.
Up 0.12 pts over 8 quarters.
Up 1.11 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 70.27 | 70.27 | 70.27 | 67.36 | 67.36 | 70.15 | 70.08 | 65.47 | -4.8 |
| FII | 0.34 | 0.25 | 0.59 | 1.18 | 1.07 | 0.91 | 0.57 | 0.46 | +0.12 |
| DII | 1.06 | 0.01 | 0.02 | 3.39 | 3.39 | 4.62 | 2.93 | 2.17 | +1.11 |
| Public | 28.34 | 29.47 | 29.12 | 28.07 | 28.18 | 24.32 | 26.43 | 31.9 | +3.56 |
Mutual fund holdings · Oct 2026
11 schemes hold this stock
7 the month before.
- Motilal Oswal Nifty Microcap 250 Index Fund0.24% of NAV
- Bandhan BSE Healthcare Index Fund0.12% of NAV
- Motilal Oswal BSE Healthcare ETF0.12% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- Bandhan Nifty Total Market Index Fund0.01% of NAV
- Groww Nifty Total Market Index Fund0.01% of NAV
- Angel One Nifty Total Market ETF0.01% of NAV
- Mirae Asset Nifty Total Market Index Fund0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SUVEN LIFE S are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about SUVEN LIFE S
What is the SUVEN LIFE S share price?
SUVEN LIFE S (SUVEN) last closed at ₹277.10, up 4.31% on the day. Its 52-week range is ₹126.65 to ₹392.05.
What is the market cap of SUVEN LIFE S?
SUVEN LIFE S has a market capitalisation of about ₹7,513 crore.
How are SUVEN LIFE S's latest results?
SUVEN LIFE S reported revenue of ₹1 crore for Sep 2026, up 0.0% from a year earlier. Net profit was ₹-107 crore. Return on equity was -46.7% in Mar 2026. Promoter holding was 65.47% in Sep 2026, down 4.80 points over 8 quarters.
Who owns SUVEN LIFE S?
As of Sep 2026, shareholding was: Promoter 65.47%, FII 0.46%, DII 2.17%, Public 31.9%.
How many mutual funds hold SUVEN LIFE S?
11 mutual fund schemes held SUVEN LIFE S in October 2026. That compares with 7 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 17 Oct 2022 · Rights issue 1:2
- 14 Feb 2019 · Interim Dividend - Rs. 1.5
- 06 Feb 2018 · Interim Dividend - Rs. 1.5
- 08 Feb 2017 · Interim Dividend - Rs. 1
- 14 Mar 2016 · Special Dividend - Rs. 1
- 23 Jul 2015 · Dividend - Rs. 0.6
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.